ScreenPoint Medical
Radboud University spin-out whose Transpara software is the AI reader tested in the MASAI screening trial.
Overview
ScreenPoint's Transpara is CE-marked and FDA-cleared for 2D and 3D mammography and is the most widely evidenced breast screening AI, used in MASAI (Sweden) and in Danish and German programmes. The company's founders come from the Nijmegen computer-aided detection group that ran the DREAM mammography challenge.
Scorecard
All companies- approved products +6
- modalities +2
- regions +2
Pages like this
not linked directly; found by shared links- CompanyKheiron Medical Technologies
Shares Mammography & tomosynthesis, AI in radiology, HR-positive / HER2-negative breast cancer.
- CompanyTherapixel
Shares Mammography & tomosynthesis, AI in radiology, HR-positive / HER2-negative breast cancer.
- CompanyVara
Shares Mammography & tomosynthesis, AI in radiology, HR-positive / HER2-negative breast cancer.
- CompanyKheiron Medical Technologies (DeepHealth)
Shares Mammography & tomosynthesis, AI in radiology, HR-positive / HER2-negative breast cancer.
- ProductLunit INSIGHT MMG
Shares Mammography & tomosynthesis, AI in radiology, HR-positive / HER2-negative breast cancer.
- CompanyiCAD (RadNet)
Shares Mammography & tomosynthesis, AI in radiology, HR-positive / HER2-negative breast cancer.
- CompanyVolpara Health
Shares Mammography & tomosynthesis, AI in radiology, HR-positive / HER2-negative breast cancer.
- ProductProFound AI (iCAD)
Shares Mammography & tomosynthesis, AI in radiology, HR-positive / HER2-negative breast cancer.